Online inquiry

IVTScrip™ mRNA-Anti-DPEP3, SC-003 mAb(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ14672MR)

This product GTTS-WQ14672MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets DPEP3 gene. The antibody can be applied in Ovarian Cancer research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001129758.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 64180
UniProt ID Q9H4B8
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-DPEP3, SC-003 mAb(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ14672MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6636MR IVTScrip™ mRNA-Anti-ITGAV, DI-17E6(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA DI-17E6
GTTS-WQ12935MR IVTScrip™ mRNA-Anti-MUC1, PankoMab(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA PankoMab
GTTS-WQ14808MR IVTScrip™ mRNA-Anti-CD70, SGN-70(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA SGN-70
GTTS-WQ945MR IVTScrip™ mRNA-Anti-EGFR, ABBV-321(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ABBV-321
GTTS-WQ1790MR IVTScrip™ mRNA-Anti-CD19, ADCT-402(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ADCT-402
GTTS-WQ15766MR IVTScrip™ mRNA-Anti-CA9, WX-G250(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA WX-G250
GTTS-WQ4600MR IVTScrip™ mRNA-Anti-KIR2DL1&KIR2DL2&KIR2DL3&KIR2DS1&KIR2DS2, BMS-986015(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA BMS-986015
GTTS-WQ13013MR IVTScrip™ mRNA-Anti-CSF3R, PEG-G-CSF(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA PEG-G-CSF
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW